Skip to main content

AC Immune SA

corporate_fare Company Profile

AC Immune SA

ACIU·NASDAQ·Life Sciences·CIK 0001651625

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA (NASDAQ:ACIU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACIU at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • AC Immune Initiates Phase 1 Clinical Trial for Novel NLRP3 Inhibitor ACI-19764 Targeting Neurodegenerative Diseases
  • AC Immune's Partner Janssen Temporarily Pauses Enrollment in Phase 2b Alzheimer's Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
CHF 3.57M CHF
Net Income
-CHF 70.45M CHF
Diluted EPS
-CHF 0.70 CHF
Op. Cash Flow
-CHF 69.26M CHF
Free Cash Flow
-CHF 70.16M CHF
Operating Income
-CHF 69.32M CHF
Cash & Equivalents
CHF 26.8M CHF
Debt / Equity
0.00×
Net Margin
-19.72×
Source: 20-F · filed 2026-03-13 · accession 0001104659-26-027342

Insider Transactions

ACIU files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.95
52-week range · as of 2026-11-04 $1.95 – $3.9
Market cap
$198.46M
Volume
298.4K (1.5× avg)
3-mo avg 205.2K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACIU - Filings & News (Page 2)

ACIU
Feb 24, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $1.95 info
Change: -$0.5532 (-22%) info
Market Cap: $198.458M info
ACIU
Feb 17, 2026, 4:36 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.91
Real-time Price: $1.95 info
Change: -$0.960 (-33%) info
Market Cap: $198.458M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets